Patient Square Capital LP
13F Reported Value
ⓘ$563.6M
Holdings
29
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Patient Square Capital LP disclosed 29 positions worth $563.6M in its Form 13F-HR for Q1 2026, led by $ROIV (Roivant Sciences Ltd.) at 40.1% of the equity portfolio, followed by $ARGX and $INSM. During the quarter the fund opened 7 new positions and exited 6 — including a new stake in $BLTE and a full exit from $TERN. The portfolio is most concentrated in Healthcare (98.2% of disclosed assets). All figures are sourced directly from Patient Square Capital LP’s Form 13F-HR filing with the SEC under CIK 1819257.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$226.2M8,166,047 sh - —
Quality
$26.8M36,718 sh - 29.4#2,409
Quality
$25.8M157,500 sh - —
Quality
$23.9M80,542 sh - —
Quality
$22.9M596,000 sh - 32.7
Quality
$21.2M230,000 sh - —
Quality
$18.6M116,684 sh - 44.2
Quality
$17.9M990,000 sh - 10.2
Quality
$15.1M210,000 sh - 6.1
Quality
$14.5M693,534 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Roivant Sciences Ltd.$ROIV | — | $226.2M | 8,166,047 |
 ARGENX SE$ARGX | — | $26.8M | 36,718 |
 INSMED Inc$INSM | 29.4#2,409 | $25.8M | 157,500 |
 BeOne Medicines Ltd.$ONC | — | $23.9M | 80,542 |
 Cogent Biosciences, Inc.$COGT | — | $22.9M | 596,000 |
 Mirum Pharmaceuticals, Inc.$MIRM | 32.7 | $21.2M | 230,000 |
 BELITE BIO, INC$BLTE | — | $18.6M | 116,684 |
 Legend Biotech Corp$LEGN | 44.2 | $17.9M | 990,000 |
 NEKTAR THERAPEUTICS$NKTR | 10.2 | $15.1M | 210,000 |
 DBV Technologies S.A.$DBVT | 6.1 | $14.5M | 693,534 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Patient Square Capital LP's 29 positions.
Showing top 10 of 29 holdings.
Sector Allocation
Healthcare
$553.4M
Technology
$10.2M
Full Holdings — Patient Square Capital LP (Q1 2026)
All 29 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ROIV | Roivant Sciences Ltd. | $226.2M | 40.1% | +0% | — |
| 2 | $ARGX | ARGENX SE | $26.8M | 4.8% | +41% | — |
| 3 | $INSM | INSMED Inc | $25.8M | 4.6% | -41% | 29.4 |
| 4 | $ONC | BeOne Medicines Ltd. | $23.9M | 4.2% | +16% | — |
| 5 | $COGT | Cogent Biosciences, Inc. | $22.9M | 4.1% | +88% | — |
| 6 | $MIRM | Mirum Pharmaceuticals, Inc. | $21.2M | 3.8% | -23% | 32.7 |
| 7 | $BLTE | BELITE BIO, INC | $18.6M | 3.3% | NEW | — |
| 8 | $LEGN | Legend Biotech Corp | $17.9M | 3.2% | NEW | 44.2 |
| 9 | $NKTR | NEKTAR THERAPEUTICS | $15.1M | 2.7% | NEW | 10.2 |
| 10 | $DBVT | DBV Technologies S.A. | $14.5M | 2.6% | +93% | 6.1 |
| 11 |  $PHVS | Pharvaris N.V. | $13.9M | 2.5% | -9% | — |
| 12 |  $ABVX | Abivax S.A. | $13.5M | 2.4% | -7% | — |
| 13 |  $XENE | Xenon Pharmaceuticals Inc. | $13.2M | 2.3% | +66% | 12.9 |
| 14 |  $CELC | Celcuity Inc. | $10.8M | 1.9% | -21% | — |
| 15 |  $EYPT | EyePoint, Inc. | $10.2M | 1.8% | +2% | 10.3 |
| 16 |  $MRK | Merck & Co., Inc. | $9.6M | 1.7% | NEW | 70.9 |
| 17 |  $ARQT | Arcutis Biotherapeutics, Inc. | $9.4M | 1.7% | +91% | 41.2 |
| 18 |  $ALLO | Allogene Therapeutics, Inc. | $8.4M | 1.5% | -30% | — |
| 19 |  $KYMR | Kymera Therapeutics, Inc. | $8.3M | 1.5% | -28% | 29.2 |
| 20 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $7.9M | 1.4% | -37% | 26.8 |
| 21 |  $ELVN | Enliven Therapeutics, Inc. | $7.8M | 1.4% | -35% | — |
| 22 |  $CATX | Perspective Therapeutics, Inc. | $6.8M | 1.2% | +43% | — |
| 23 |  $DFTX | Definium Therapeutics, Inc. | $6.3M | 1.1% | NEW | — |
| 24 |  $HROW | HARROW, INC. | $5.8M | 1.0% | +2250% | 41.6 |
| 25 |  $TARA | Protara Therapeutics, Inc. | $5.4M | 0.9% | NEW | — |
| 26 |  $CTMX | CytomX Therapeutics, Inc. | $5.1M | 0.9% | NEW | 19.1 |
| 27 |  $RCUS | Arcus Biosciences, Inc. | $4.2M | 0.8% | +15% | 12 |
| 28 |  $ASMB | ASSEMBLY BIOSCIENCES, INC. | $3.8M | 0.7% | +7% | 26.6 |
| 29 |  $SYRE | Spyre Therapeutics, Inc. | $50,440 | 0.0% | -99% | — |
New Positions (7)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Patient Square Capital LP including:
Track Patient Square Capital LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Patient Square Capital LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Patient Square Capital LP
13F Pro is an AI hedge fund tracker and stock research platform. For Patient Square Capital LP (SEC CIK: 1819257), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Patient Square Capital LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.